- Home
- WDAY vs INSM Comparison
WDAY vs INSM Comparison
Compare WDAY & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WDAY | INSM |
|---|---|---|
| Founded | 2005 | 1988 |
| Country | United States | United States |
| Employees | 21000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 30.1B |
| IPO Year | 2012 | 2000 |
Fundamental Metrics
Financial Performance| Metric | WDAY | INSM |
|---|---|---|
| Price | $117.68 | $152.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 34 | 24 |
| Target Price | ★ $202.50 | $200.48 |
| AVG Volume (30 Days) | ★ 4.6M | 2.3M |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $2,143,050,000.00 | N/A |
| Revenue This Year | $13.80 | $177.03 |
| Revenue Next Year | $11.30 | $66.55 |
| P/E Ratio | $59.04 | ★ N/A |
| Revenue Growth | ★ 36.55 | N/A |
| 52 Week Low | $110.36 | $63.81 |
| 52 Week High | $276.00 | $212.75 |
Technical Indicators
Market Signals| Indicator | WDAY | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 50.19 |
| Support Level | N/A | $136.24 |
| Resistance Level | $132.69 | $166.81 |
| Average True Range (ATR) | 5.78 | 6.16 |
| MACD | -0.43 | -0.04 |
| Stochastic Oscillator | 33.13 | 52.27 |
Price Performance
Historical ComparisonAbout WDAY Workday Inc.
Workday is a software company that offers human capital management, financial management, and business planning solutions for enterprises. Known for being a cloud-only software provider, Workday was founded in 2005 and is headquartered in Pleasanton, California.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.